|
h******r
发帖数: 294 | 2 你同事原来是做什么方面工作的？R&D 还是 manufacture？ |
|
|
c***a
发帖数: 38 | 4 But share holders definitely love him. |
|
l*****k
发帖数: 587 | 5 exactly the point, w street rules, untill they fail |
|
c********a
发帖数: 86 | 6 不过他当CEO这些年，SP还是比以前景气了不少的。不少在里面做的朋友对他的评价还
是挺高的。 |
|
|
|
|
t*******e
发帖数: 13 | 10 SP是独一无二pipeline里有货的，被搞是板上钉钉的。 |
|
|
|
d***1
发帖数: 401 | 13 偶觉得这个CEO挺能干的，非常有商业头脑，活该赚这么多钱。 |
|
p*****0
发帖数: 3104 | 14 他是为他的股东负责 而不是对手下的员工负责
想象spiderman中的harry的父亲 |
|
m**********2
发帖数: 6568 | 15 exactly.
many boards specifically look for this kind of person to hire, for the sole
purpose of turning stock into profit.
after all, the essence of capitalism is: capital--->profit. everything else
is just a tool. |
|
|
l*******d
发帖数: 22 | 17 more like an pakistanian ... |
|
|
F********r
发帖数: 407 | 19 Fred is a Pakistanian and was educated in Europe. I left SP a little more
than 2.5 years ago. At that time, the annual sales went down to $9 billion.
4-5 products in pipeline. Before that, SP was under FDA consent decree.
He led the company went through that. Last year, the annual sales was 18
billion (with acquisition) and the best pipeline in the industry. That is
why he is considered as the pro in turn-around in Pharm business. |
|
m****g
发帖数: 988 | 20 看到merck的rahway site有opening，他们会一边裁人一边招人吗？ |
|
t**n
发帖数: 4365 | 21 merck is hiring masters and laying off phds |
|
|
s********s
发帖数: 579 | 23 NJ的血雨腥风马上就要来啦!
layoff肯定不会少。现在合并主要就是用来layoff. |
|
b**********a
发帖数: 930 | 24 现在制药公司合并主要目的之一就是减少开支（其他主要目的是整合业务，从对方的
pipelines或portfolio来弥补自己的不足），而人工的开支在西方至少要占整个开支的
50%以上，一般都要对销售进行整合，可能也是最大的整合，所以layoff是必然的，对
于研发来说，重叠研发部分肯定要动大手术。公司如果好的话可能会给员工比较好的
package吧，但是目前情况下都不会好到那里去。对中国人来说，95%都是做技术，现在
国内做制药CROs的很多，也是很好的机会。记住把一些重要的东西留下给自己，不要很
快copy东西，慢慢来，不然会给人把柄很麻烦。 |
|
|
s********s
发帖数: 579 | 26 blueskychina
明显就是懂行的阿。
想不被layoff重要的一点就是从研发转到商务或者管理。 |
|
b**********a
发帖数: 930 | 27 想不被layoff重要的一点就是从研发转到商务或者管理。
你以为谁不想转了去做管理或商务啊，在西方人的制药研发公司你华人想做管理，要么
是你根本就没有在这类药厂做过，要么你根本就不懂。 |
|
N***n
发帖数: 660 | 28 做个小老板还是行的吧？管理也不一定就得是VP一级啊 |
|
a***n
发帖数: 1355 | 29 很多药厂layoff的时候，从商务开始， 然后才是研发
一线经理一点也不比研发scientist 安全 |
|
s********s
发帖数: 579 | 30 要有计划还有就是把握机会，很多老美（包括tw,新加坡人）当年（05-07年）就是看出
搞研发有危险，从研发奋力跳去做项目管理，采购，QA，我也是从研发出来做的外包生
产技术管理的，在意大利和爱尔兰base了半年，还好当时没成家。
当时很多中国的同事都喜欢做研发，你也知道，研发管的松，出差又少，帮老婆做家务
，接送孩子都方便，做商务，管理，采购，钱不多拿，但是要累不少，所以内部广告出
来的时候，当时我们部门结婚的老中都没兴趣。 |
|
s********9
发帖数: 423 | 31 是难点, 但我知道华人有当regulatory manager的. |
|
k********s
发帖数: 320 | 32 My my, I'd thought Schering Plough has the most complicated scientific
ladder, BMS beats it hands down... |
|
t**n
发帖数: 4365 | 33 来自主题: Pharmaceutical版 - 公司药店 原Schering-Plough有Clariton，各种鞋垫，防晒霜，不知道Merck的能不能买
MERCK |
|
t**n
发帖数: 4365 | 34 ☆─────────────────────────────────────☆
Lilycat (婆猫) 于 (Sun Nov 18 23:59:31 2007) 提到:
Biogen, Scientist I
BMS, Research Investigator I
Boehringer ingelheim, Senior Scientist
GSK, Principal Scientist
Affymax, Staff Scientist
Abbott, Senior Scientist
Covance, Staff Scientist
☆─────────────────────────────────────☆
bleu (Crystal Jade 翡翠小厨) 于 (Mon Nov 19 11:08:50 2007) 提到:
Schering Plough应该也是Senior Scientist吧。
☆─────────────────────────────────────☆
mklb (wisher_washer) 于 (Mon Nov 19 1 |
|
k********s
发帖数: 320 | 35 This is much too generalized and will be confusing to people. Which
location are you referring to? Northeast, PA, North Carolina, Indiana,
Illinois or California? And Ph.D in what area, organic chemistry,
analytical chemistry, biology or statistics? There ARE significant
difference.
Besides, your bonus info. is misleading, I'm not saying those kinds of
bonus are not happening in some companies, that it might be. But it is
NOT the case with Pfizer, Novartis, former Schering Plough, Merck, BMS,
an |
|
f********e
发帖数: 2194 | 36 的确是过时了，不过就算Merck+Schering-Plough的revenue也小于40b,进不了前五 |
|
b**u
发帖数: 2761 | 37 来自主题: Pharmaceutical版 - 药厂的工作 schering plough
仙灵宝雅，被merck收购重组了，大概两年多前的事 |
|
k*****h
发帖数: 18 | 38 去年2月成立的,不知道具体是做什么的,望高人指点. |
|
P***e
发帖数: 804 | 39 On Tuesday, Sanofi said it agreed to pay $20.1 billion or $74 per share to
acquire Genzyme. The acquisition is the biggest drug deal since Merck &
Co. agreed to buy Schering-Plough Corp. for $47.1 billion, in 2009.
Full text here:
http://bostonherald.com/business/general/view.bg?
articleid=1317504&position=0 |
|
b**u
发帖数: 2761 | 40 By PETER LOFTUS
Merck & Co. said Friday that it would widen its cost-cutting measures by
eliminating up to 13,000 jobs—on top of the 17,000 layoffs in prior actions
—as the drug maker faces generic competition and other pressures.
The Whitehouse Station, N.J., company disclosed the job cuts as it reported
a near-tripling of second-quarter earnings on a tax benefit and other items.
Revenue rose 7% on sales growth for diabetes drugs Januvia and Janumet, as
well as anti-inflammatory drug Remicade.
... 阅读全帖 |
|
v******V
发帖数: 314 | 41 【 以下文字转载自 Pharmaceutical 讨论区 】
发信人: ErWang (王二), 信区: Pharmaceutical
标 题: 几个公司的来历
发信站: BBS 未名空间站 (Sun Dec 4 11:45:34 2005)
制药工业基本是大鱼吃小鱼, 偶尔也有小麻雀吃大ham的(如Sanofi-Aventis). 只有Merck
比较noble (tends to eat Shering-Plough), 可惜倒霉了.
1.Pfizer
(1) pharmacia + UpJohn + Sugen --> Pharmacia
(2) G.D.Searle+ Monsanto --------> Monsanto
(3) (1) + (2) - Monsanto (Ag) ---> Pharmacia
(4) Warner-Hudnut + Lambert + Parke-Davis --> Warner-Lambert
(5) Pfizer + (4) --> Pfizer
(6) (5) + (3) --> Pfizer
2.GSK
(1) SK&F + |
|
j*****7
发帖数: 4348 | 42 这和老中太多没什么关系, 主要是大药厂的专利都快到期了, 这行当又是烧钱机器.
总结一下俺知道的有关的大药厂消息:
MRK: 和Shering Plough合并后裁了一批programmer, statistician好像还没动.
SNY: 美国分部裁2500, 和Covance签了大合同
LILY: 裁80个statistican and medical writer, 和A3签了大合同(从两年前起)
GSK: 裁过了
ABT: NJ的site关闭了
PFE: 裁了很多
BMY: 正式开展大规模的和CRO的合作. |
|
j*****7
发帖数: 4348 | 43 Merck的工资原来是真心的低。和Schering-Plough合并后不知怎么样了。 |
|
N***i
发帖数: 2063 | 44 http://www.zacks.com/stock/news/37221/Pharma+and+Biotech+Industry+Outlook+-+July+2010
By: Zacks Equity Research
July 20, 2010 | Comments: 0
Recommended this article (2)
ABT | JNJ | PFE | MRK | RHHBY | BMY | SNY | MYL | LLY | GSK | ACL | GILD |
BIIB | AMLN
Print Share
The pharmaceutical industry has witnessed major changes over the past few
quarters, with performance being affected by factors like sluggish
prescription trends, intensifying generic competition and limited late-stage
catalysts. ... 阅读全帖 |
|
v**********m
发帖数: 5516 | 45 由于这个？
Dendreon Agrees to Sell VICTRELIS(TM) (boceprevir) Royalty Interest for $125
Million
SEATTLE, Dec 06, 2011 (BUSINESS WIRE) -- Dendreon Corporation DNDN -0.11%
today announced that it has agreed to sell for $125 million in cash its
royalty interest related to intellectual property licensed to Schering-
Plough Ltd. and Schering Corporation (collectively Schering, each now a
wholly owned subsidiary of Merck & Co., Inc.) and associated with VICTRELIS(
TM) (boceprevir), a treatment for chronic... 阅读全帖 |
|
